Supplementary Figure S1 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

crossref(2024)

引用 0|浏览5
暂无评分
摘要

Supplementary Figure 1. Nonclinical Mechanisms of Potential Ineffective Dual AR/GR Inhibition

更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要